Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.75 |
| ▸ | EGFR | P00533 | 15/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 13/20 | 0.75 |
| ▸ | FLT1 | P17948 | 13/20 | 0.75 |
| ▸ | FLT4 | P35916 | 13/20 | 0.75 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.71 |
| ▸ | RET | P07949 | 3/20 | 0.71 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.71 |
| ▸ | TEK | Q02763 | 2/20 | 0.71 |
| ▸ | KIF5B | P33176 | 2/20 | 0.71 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.71 |
| ▸ | PLK4 | O00444 | 1/20 | 0.71 |
| ▸ | CIT | O14578 | 1/20 | 0.71 |
| ▸ | GAK | O14976 | 1/20 | 0.71 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.71 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.71 |
| ▸ | STK10 | O94804 | 1/20 | 0.71 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1612820 | 0.94 | KDR (0.84) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL31319937 | 0.94 | KDR (0.84) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL4025000 | 0.92 | KDR (0.73) | KDREGFRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL1783178 | 0.89 | EGFR (0.89) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL13458879 | 0.86 | KDR (0.66) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL5424040 | 0.85 | KDR (1.00) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL2136908 | 0.85 | EGFR (1.00) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL2140901 | 0.84 | FLT1 (0.98) | KDREGFRFGFR1FLT1FLT4 | |
| Hydrochloric Acid SCHEMBL27218181 | 0.84 | FLT1 (1.00) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL17520370 | 0.83 | KDR (0.79) | KDREGFRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609673-B2 | Vandetanib derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20110117084-A1 | VANDETANIB DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2009094210-A1 | VANDETANIB DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117084-A1 | VANDETANIB DERIVATIVES | KDR, VHL, FLT4 | KDR 1/4885EGFR 17/4885FGFR1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.